CN114225045B - 代谢功能障碍引起的肿瘤的治疗 - Google Patents

代谢功能障碍引起的肿瘤的治疗

Info

Publication number
CN114225045B
CN114225045B CN202111316615.1A CN202111316615A CN114225045B CN 114225045 B CN114225045 B CN 114225045B CN 202111316615 A CN202111316615 A CN 202111316615A CN 114225045 B CN114225045 B CN 114225045B
Authority
CN
China
Prior art keywords
cancer
compound
present disclosure
tumor
certain aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111316615.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114225045A (zh
Inventor
J.沙纳汉
P.科内柳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SynDevRX Inc
Original Assignee
SynDevRX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SynDevRX Inc filed Critical SynDevRX Inc
Publication of CN114225045A publication Critical patent/CN114225045A/zh
Application granted granted Critical
Publication of CN114225045B publication Critical patent/CN114225045B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202111316615.1A 2016-01-11 2017-01-11 代谢功能障碍引起的肿瘤的治疗 Active CN114225045B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662277293P 2016-01-11 2016-01-11
US62/277293 2016-01-11
US201662393929P 2016-09-13 2016-09-13
US62/393929 2016-09-13
US201662395446P 2016-09-16 2016-09-16
US62/395446 2016-09-16
PCT/US2017/012968 WO2017123603A1 (en) 2016-01-11 2017-01-11 Treatment for tumors driven by metabolic dysfunction
CN201780016316.1A CN108697807B (zh) 2016-01-11 2017-01-11 代谢功能障碍引起的肿瘤的治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780016316.1A Division CN108697807B (zh) 2016-01-11 2017-01-11 代谢功能障碍引起的肿瘤的治疗

Publications (2)

Publication Number Publication Date
CN114225045A CN114225045A (zh) 2022-03-25
CN114225045B true CN114225045B (zh) 2025-09-26

Family

ID=57882196

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780016316.1A Active CN108697807B (zh) 2016-01-11 2017-01-11 代谢功能障碍引起的肿瘤的治疗
CN202111316615.1A Active CN114225045B (zh) 2016-01-11 2017-01-11 代谢功能障碍引起的肿瘤的治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780016316.1A Active CN108697807B (zh) 2016-01-11 2017-01-11 代谢功能障碍引起的肿瘤的治疗

Country Status (9)

Country Link
US (3) US10646463B2 (enExample)
EP (1) EP3402529A1 (enExample)
JP (3) JP7022066B2 (enExample)
KR (1) KR20180100663A (enExample)
CN (2) CN108697807B (enExample)
AU (3) AU2017206718B2 (enExample)
CA (2) CA3008960C (enExample)
MX (2) MX2018008321A (enExample)
WO (1) WO2017123603A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP3858385B1 (en) * 2010-05-25 2024-09-11 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
CN108290853B (zh) 2015-12-10 2022-05-31 辛德弗雷克斯公司 烟曲霉醇衍生物及其多晶型物
CA3008960C (en) 2016-01-11 2024-07-02 Syndevrx, Inc. TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
EP3870231A1 (en) * 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
CN112915210B (zh) * 2019-12-06 2024-08-20 重庆阿普格雷生物科技有限公司 一种聚乙二醇偶联药物、其制备方法及应用
AU2021378944A1 (en) * 2020-11-11 2023-06-15 Syndevrx, Inc. Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer
CN116887836A (zh) * 2020-11-11 2023-10-13 辛德弗雷克斯公司 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
CA3264343A1 (en) * 2022-08-10 2024-02-15 Syndevrx, Inc. METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS
KR20250117799A (ko) * 2022-11-16 2025-08-05 신데브알엑스, 인크. 전립선암의 치료를 위한 metap2 억제제
CN119932197B (zh) * 2025-04-09 2025-06-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140512A (zh) * 2010-05-25 2013-06-05 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
AU9376998A (en) 1997-09-02 1999-03-22 Johns Hopkins University School Of Medicine, The Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
AU3352799A (en) 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
BR9910092A (pt) 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
EP1155702A4 (en) 1998-10-30 2004-12-15 Daiichi Seiyaku Co DDS CONNECTIONS AND TEST METHODS
WO2001018080A1 (en) 1999-09-08 2001-03-15 School Of Pharmacy, University Of London Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7087768B2 (en) 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
WO2003070173A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003230852B2 (en) 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
WO2006084054A2 (en) 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
SG185954A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
NZ585547A (en) 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
US20100272717A1 (en) * 2007-12-13 2010-10-28 Novartis Ag Combinations of therapeutic agents for treating cancer
CN102105156B (zh) 2008-05-22 2016-05-25 特拉维夫大学拉莫特有限公司 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
TWI373345B (en) 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
MX343135B (es) * 2010-01-08 2016-10-25 Zafgen Corp * Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2575887A4 (en) * 2010-05-25 2015-01-14 SynDevRX CONJUGATES OF OPTIMIZED MEDICINES
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
PH12013500934A1 (en) * 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
BR122017028566B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A. Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
HRP20211879T1 (hr) * 2013-08-14 2022-03-04 Novartis Ag Kombinirana terapija za liječenje raka
CN108290853B (zh) 2015-12-10 2022-05-31 辛德弗雷克斯公司 烟曲霉醇衍生物及其多晶型物
CA3008960C (en) * 2016-01-11 2024-07-02 Syndevrx, Inc. TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION
US11319376B2 (en) 2016-08-03 2022-05-03 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
EP3870231A1 (en) * 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140512A (zh) * 2010-05-25 2013-06-05 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法

Also Published As

Publication number Publication date
AU2021286420A1 (en) 2022-01-20
MX2018008321A (es) 2018-09-21
CN114225045A (zh) 2022-03-25
AU2017206718B2 (en) 2021-09-30
WO2017123603A1 (en) 2017-07-20
US20220280470A1 (en) 2022-09-08
AU2024204027A1 (en) 2024-07-04
JP7022066B2 (ja) 2022-02-17
CN108697807B (zh) 2021-11-26
KR20180100663A (ko) 2018-09-11
JP2025071236A (ja) 2025-05-02
CA3008960C (en) 2024-07-02
JP7640481B2 (ja) 2025-03-05
US10646463B2 (en) 2020-05-12
MX2023002076A (es) 2023-03-17
US20210077452A1 (en) 2021-03-18
US20170196830A1 (en) 2017-07-13
CN108697807A (zh) 2018-10-23
AU2021286420B2 (en) 2024-03-14
US11273142B2 (en) 2022-03-15
JP2022048388A (ja) 2022-03-25
JP2019501206A (ja) 2019-01-17
AU2017206718A1 (en) 2018-07-05
CA3239447A1 (en) 2017-07-20
EP3402529A1 (en) 2018-11-21
CA3008960A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CN114225045B (zh) 代谢功能障碍引起的肿瘤的治疗
US11739069B2 (en) Modulators of resistant androgen receptor
TW202038951A (zh) 用於治療癌症之醫藥組合
EP2558085B1 (en) Compositions and methods for the prevention and treatment of cancer
KR102346033B1 (ko) 단백질 타이로신 키나아제 조절인자로서의 ｎ-(3-플루오로벤질)-2-(5-(4-모르폴리노페닐)피리딘-2-일)아세트아미드
JP2020172531A (ja) 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
US8575191B2 (en) Methods for treatment of non-small cell lung cancer
TW201315470A (zh) 吡咯並喹啉基－吡咯啶－２，５－二酮調製劑類及製備和使用彼等之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant